An interventional study of Multiparametric ultrasound with contrast (Sonovue and Optison) in Prostate Cancer, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Not yet recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).
Among the 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), this one is one of 2 that started in 2025, is one of 8 with no phase, and was the 10th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) are open now, in 1 country. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 212 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 210 across the 8 interventional studies, 404 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is the lead sponsor of 533 studies on the registry; 182 are open to participants now.
1 of the studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06935487Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)European Multicenter Validation of PCaVision: A Head-to-Head Diagnostic Accuracy Study Comparing Multiparametric Transrectal Ultrasound to MRI for Clinically Significant Prostate Cancer Detection | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective clinical study aims to retrain and validate the PCaVision AI algorithm for the detection and localization of clinically significant prostate cancer (csPCa) using multiparametric ultrasound (mpUS) with two different ultrasound contrast agents: Sonovue and Optison. Data will be collected using a commercial version of the LOGIQ E10 ultrasound machine, with full histopathological correlation in patients undergoing radical prostatectomy.
The PCaVision CAD system was initially developed using Sonovue contrast and a research-only ultrasound machine (LOGIQ E10 R3). In this study, the algorithm will be retrained using data acquired from the LOGIQ E10 R4, a commercially available system, and using both Sonovue and Optison as contrast agents. The goal is to enhance generalizability and enable broader clinical adoption. The study includes two cohorts: patients scheduled for radical prostatectomy (for training and voxel-level validation) and patients with a negative prostate MRI (for patient-level specificity evaluation). All participants will undergo 3D transrectal mpUS with both contrast agents in a single session. Full prostate histology from RP specimens will serve as the reference standard.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic test: Multiparametric ultrasound with contrast (Sonovue and Optison)
Diagnostic Test: Multiparametric ultrasound with contrast (Sonovue and Optison)
Participants will receive 3D mpUS using both Sonovue and Optison contrast agents during a single transrectal imaging session.
Sensitivity and Specificity of PCaVision Algorithm (Sonovue and Optison) Compared to Histopathology
Sensitivity and specificity of the PCaVision algorithm in detecting and localizing clinically significant prostate cancer (csPCa, Gleason Grade Group ≥2) at the voxel level, based on 3D multiparametric ultrasound (mpUS) images using Sonovue and Optison, validated against full prostate histology after radical prostatectomy.
Time frame: From baseline imaging to histopathology report (typically within 2-4 weeks post-surgery)
Specificity of PCaVision in MRI-Negative Cohort
Evaluation of the specificity of the PCaVision algorithm for csPCa detection at the patient level in men with a negative prostate MRI (PI-RADS ≤2), using mpUS imaging with Sonovue and Optison.
Time frame: From baseline imaging to completion of image processing and analysis (within 2 weeks of scan)
Diagnostic Performance Comparison Between Sonovue and Optison
Head-to-head comparison of diagnostic performance (sensitivity, specificity, AUC) of PCaVision on mpUS scans obtained with Sonovue versus Optison, using RP histopathology as reference. Evaluated at voxel level and using simulated biopsy protocols.
Time frame: Imaging and analysis completed within 4 weeks post-surgery
Plan to share: No — Individual participant data (IPD) will not be shared for this study because the imaging data and histopathology are linked to highly sensitive clinical records. Due to privacy concerns and the risk of re-identification, even in coded form, sharing of raw participant-level data is not planned. Data will only be used internally for algorithm development and validation under strict confidentiality agreements.
Start is estimated for Jul 2025; primary completion for Jul 2026, 12 months later.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) →